Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508321354> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2508321354 abstract "e16039 Background: A prognostic index developed at MSKCC(Memorial-Sloan-Kettering Cancer Center) relates to survival in mRCC patients (pts) treated with interferon. We evaluated 79 pts treated first line with HDIL2 to see if this prognostic index is applicable. Eligibility for HDIL2 was based on cardiopulmonary screening and performance status (PS). Method: Medical records were analyzed retrospectively from 2000–2008. Pts were categorized into favorable, intermediate & poor risk category according to MSKCC prognostic index, which includes time from diagnosis to treatment, serum calcium & LDH, hemoglobin and PS. Median survival (OS) & median progression free survival (PFS) were compared between risk categories. Results were evaluated taking into consideration potential confounders such as subsequent treatment with tyrosine kinase inhibitors (TKI) & time from nephrectomy to metastasis interval of more than 1 year. Statistical analysis utilized SPSS. Results: 29 pts (36.7%) were treated with TKIs subsequently and this had no impact on median OS compared to those not receiving TKIs. 19 pts (24%) had nephrectomy to metastasis interval of more than 1 year and this also did not impact on OS analysis compared to those with shorter time to metastasis. Poor risk group was not analyzed due to small sample size. Conclusions: Median OS for mRCC pts eligible for and treated with HDIL2 as first line therapy exceeds reports of other first line treatment, either cytokines or TKIs. The survival advantage occurs regardless of being in either favorable or intermediate risk category and this benefit is not confounded by subsequent treatment with TKIs or nephrectomy to treatment interval more than 1 year. HDIL2 pts requires good PS and organ function, but 72% were intermediate risk pts. Thus, MSKCC risk categories do not predict for HDIL2 treatment outcome. HDIL2 should still be considered as a first line agent for mRCC, in the era of TKIs, as long as patients meet the eligibility criteria, as it infers survival advantage. [Table: see text] [Table: see text]" @default.
- W2508321354 created "2016-09-16" @default.
- W2508321354 creator A5012284766 @default.
- W2508321354 creator A5012770204 @default.
- W2508321354 creator A5033346506 @default.
- W2508321354 creator A5052502105 @default.
- W2508321354 creator A5059082327 @default.
- W2508321354 creator A5072077598 @default.
- W2508321354 creator A5089619585 @default.
- W2508321354 date "2009-05-20" @default.
- W2508321354 modified "2023-09-26" @default.
- W2508321354 title "Survival advantage in patients treated with high-dose interleukin-2 (HDIL2) for metastatic renal cell carcinoma (mRCC)" @default.
- W2508321354 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e16039" @default.
- W2508321354 hasPublicationYear "2009" @default.
- W2508321354 type Work @default.
- W2508321354 sameAs 2508321354 @default.
- W2508321354 citedByCount "0" @default.
- W2508321354 crossrefType "journal-article" @default.
- W2508321354 hasAuthorship W2508321354A5012284766 @default.
- W2508321354 hasAuthorship W2508321354A5012770204 @default.
- W2508321354 hasAuthorship W2508321354A5033346506 @default.
- W2508321354 hasAuthorship W2508321354A5052502105 @default.
- W2508321354 hasAuthorship W2508321354A5059082327 @default.
- W2508321354 hasAuthorship W2508321354A5072077598 @default.
- W2508321354 hasAuthorship W2508321354A5089619585 @default.
- W2508321354 hasConcept C121608353 @default.
- W2508321354 hasConcept C126322002 @default.
- W2508321354 hasConcept C141071460 @default.
- W2508321354 hasConcept C143998085 @default.
- W2508321354 hasConcept C2777472916 @default.
- W2508321354 hasConcept C2779490328 @default.
- W2508321354 hasConcept C2780091579 @default.
- W2508321354 hasConcept C2780227381 @default.
- W2508321354 hasConcept C2781068499 @default.
- W2508321354 hasConcept C71924100 @default.
- W2508321354 hasConcept C90924648 @default.
- W2508321354 hasConceptScore W2508321354C121608353 @default.
- W2508321354 hasConceptScore W2508321354C126322002 @default.
- W2508321354 hasConceptScore W2508321354C141071460 @default.
- W2508321354 hasConceptScore W2508321354C143998085 @default.
- W2508321354 hasConceptScore W2508321354C2777472916 @default.
- W2508321354 hasConceptScore W2508321354C2779490328 @default.
- W2508321354 hasConceptScore W2508321354C2780091579 @default.
- W2508321354 hasConceptScore W2508321354C2780227381 @default.
- W2508321354 hasConceptScore W2508321354C2781068499 @default.
- W2508321354 hasConceptScore W2508321354C71924100 @default.
- W2508321354 hasConceptScore W2508321354C90924648 @default.
- W2508321354 hasLocation W25083213541 @default.
- W2508321354 hasOpenAccess W2508321354 @default.
- W2508321354 hasPrimaryLocation W25083213541 @default.
- W2508321354 isParatext "false" @default.
- W2508321354 isRetracted "false" @default.
- W2508321354 magId "2508321354" @default.
- W2508321354 workType "article" @default.